Focused On-demand Library for Carboxylesterase 5A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6NT32

UPID:

EST5A_HUMAN

Alternative names:

Carboxylesterase-like urinary excreted protein homolog

Alternative UPACC:

Q6NT32; B7Z252; B7ZLB6; Q8NBC8; Q96DN9

Background:

Carboxylesterase 5A, also known as Carboxylesterase-like urinary excreted protein homolog, plays a crucial role in the detoxification of xenobiotics and the activation of ester and amide prodrugs. Its unique enzymatic activity is pivotal in metabolizing a wide array of substances, ensuring cellular protection against potentially harmful compounds.

Therapeutic significance:

Understanding the role of Carboxylesterase 5A could open doors to potential therapeutic strategies. Its involvement in drug metabolism and detoxification processes highlights its importance in pharmacokinetics and the development of novel drug delivery systems.